Clinical Trial Expertise Key To Early-Stage Company Deals – Medtronic COO
This article was originally published in The Gray Sheet
Executive Summary
Clinical data quality and integrity should be the main consideration for manufacturers evaluating a merger or alliance with an early-stage technology developer, according to Medtronic COO Bill Hawkins
You may also be interested in...
Device Firms Will Collaborate With Pharma, Rather Than Merge – Hawkins
Mergers of drug discovery companies with device developers will remain rare, even as collaborations across the drug, device and biologics industries become more common, Medtronic COO Bill Hawkins maintains
Cardiac Monitor Maker Courts Payment Latitude Prior To Home-Use Launch
Guidant says it will release a home-use version of its Latitude advanced patient management (APM) system upon gaining a CPT code to drive reimbursement
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.